MA52285A - Anticorps multispécifiques et leur utilisation - Google Patents
Anticorps multispécifiques et leur utilisationInfo
- Publication number
- MA52285A MA52285A MA052285A MA52285A MA52285A MA 52285 A MA52285 A MA 52285A MA 052285 A MA052285 A MA 052285A MA 52285 A MA52285 A MA 52285A MA 52285 A MA52285 A MA 52285A
- Authority
- MA
- Morocco
- Prior art keywords
- multispecific antibodies
- multispecific
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18168053 | 2018-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52285A true MA52285A (fr) | 2021-02-24 |
Family
ID=62025743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052285A MA52285A (fr) | 2018-04-18 | 2019-04-17 | Anticorps multispécifiques et leur utilisation |
Country Status (19)
Country | Link |
---|---|
US (1) | US20210147554A1 (fr) |
EP (1) | EP3781594A1 (fr) |
JP (2) | JP2021521785A (fr) |
KR (1) | KR20210005639A (fr) |
CN (1) | CN111989343B (fr) |
AR (1) | AR115052A1 (fr) |
AU (1) | AU2019256744A1 (fr) |
BR (1) | BR112020021111A2 (fr) |
CA (1) | CA3095547A1 (fr) |
CL (1) | CL2020002539A1 (fr) |
CO (1) | CO2020012360A2 (fr) |
IL (1) | IL277559A (fr) |
MA (1) | MA52285A (fr) |
MX (1) | MX2020010946A (fr) |
PE (1) | PE20210517A1 (fr) |
PH (1) | PH12020500667A1 (fr) |
SG (1) | SG11202009692SA (fr) |
TW (1) | TW201945394A (fr) |
WO (1) | WO2019202041A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
EP3820904A2 (fr) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | Anticorps se liant à ilt4 |
CN113528448B (zh) * | 2020-04-14 | 2023-01-24 | 同济大学 | 一种人胚胎干细胞的构建方法 |
AU2021286650A1 (en) * | 2020-06-11 | 2023-01-19 | Tizona Therapeutics | Bispecific immune cell engagers with binding specificity for HLA-G and another antigen |
EP4188439A2 (fr) * | 2020-07-29 | 2023-06-07 | Janssen Biotech, Inc. | Protéines comprenant des domaines de liaison à l'antigène hla-g et leurs utilisations |
EP4263609A1 (fr) * | 2020-12-17 | 2023-10-25 | F. Hoffmann-La Roche AG | Anticorps anti-hla-g et leur utilisation |
US12012454B2 (en) * | 2021-03-24 | 2024-06-18 | China Medical University Hospital | Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same |
US11795227B2 (en) * | 2021-03-24 | 2023-10-24 | Shine-On Biomedical Co., Ltd. | Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same |
CN113398253B (zh) * | 2021-05-14 | 2023-01-24 | 北京化工大学 | β2微球蛋白聚集抑制剂 |
AU2022280063A1 (en) * | 2021-05-26 | 2024-01-04 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor to target hla-g-positive cancers |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8211999B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2405246A1 (fr) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2103059C (fr) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Methode de production d'anticorps humanises |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
CA2116774C (fr) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression dans e. coli de fragments d'anticorps ayant au moins une cysteine presente sous forme de thiol libre. utilisation pour la production d'anticorps f(ab') bifonctionnels |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
CA2129663C (fr) | 1992-02-06 | 2005-07-05 | James S. Huston | Proteine fixatrice biosynthetique pour marqueur du cancer |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
AU2002228745A1 (en) | 2000-10-23 | 2002-05-06 | Rajagopalan, Sumati | Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
EP1513879B1 (fr) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Bibliotheques de phages et anticorps synthetiques |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
WO2004106381A1 (fr) | 2003-05-31 | 2004-12-09 | Micromet Ag | Compositions pharmaceutiques comprenant des constructions d'anticorps anti-cd3, anti-cd19 bispecifiques pour le traitement de troubles associes aux lymphocytes b |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
WO2006034488A2 (fr) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Anticorps et conjugués produits avec de la cystéine |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP3623473A1 (fr) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
EP2465870A1 (fr) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Polypeptides de liaison dotés de séquences hypvervariables VH/VL diversifiées et consensuelles |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
CA2651567A1 (fr) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Polypeptides de liaison a squelettes optimises |
WO2007147901A1 (fr) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
MX2011010159A (es) | 2009-04-02 | 2011-10-17 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla. |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
EP2435473B1 (fr) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Anticorps tri ou tétra-spécifiques |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011034605A2 (fr) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations |
ME02505B (fr) | 2009-12-29 | 2017-02-20 | Aptevo Res & Development Llc | Protéines de liaison hétérodimères et utilisations de celles-ci |
EP2569337A1 (fr) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Protéines hétérodimériques et leurs procédés de production et de purification |
RS59589B1 (sr) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu |
KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
CA2837975C (fr) | 2011-08-23 | 2022-04-05 | Roche Glycart Ag | Molecules bispecifiques de liaison a l'antigene activant les lymphocytes t. |
PL2748202T3 (pl) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Dwuswoiste cząsteczki wiążące antygen |
CN107586340B (zh) * | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 |
DK2794905T3 (da) | 2011-12-20 | 2020-07-06 | Medimmune Llc | Modificerede polypeptider til bispecifikke antistofgrundstrukturer |
MX360352B (es) | 2012-02-15 | 2018-10-30 | Hoffmann La Roche | Cromatografia de afinidad basada en receptores fc. |
NZ772318A (en) | 2012-04-20 | 2023-06-30 | Merus Nv | Methods and means for the production of ig-like molecules |
KR20230155605A (ko) | 2013-12-20 | 2023-11-10 | 제넨테크, 인크. | 이중 특이적 항체 |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
KR102170533B1 (ko) * | 2014-04-03 | 2020-10-27 | 셀렉티스 | 암 면역요법을 위한 cd33 특이적 키메라 항원 수용체들 |
EP3174897B1 (fr) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Anticorps multi-spécifiques |
DK3608337T3 (da) | 2014-08-04 | 2024-06-17 | Hoffmann La Roche | Bispecifikke T-celleaktiverende antigenbindende molekyler |
EP3209684B1 (fr) | 2014-10-24 | 2020-12-23 | F.Hoffmann-La Roche Ag | Humanisation d'anticorps à base d'angle vh-vl-interdomaine |
US20190119385A1 (en) * | 2015-03-27 | 2019-04-25 | University Of Southern California | Hla-g as a novel target for car t-cell immunotherapy |
KR20240093813A (ko) | 2015-04-24 | 2024-06-24 | 제넨테크, 인크. | 다중특이적 항원-결합 단백질 |
-
2019
- 2019-04-16 AR ARP190101003A patent/AR115052A1/es unknown
- 2019-04-17 BR BR112020021111-7A patent/BR112020021111A2/pt not_active Application Discontinuation
- 2019-04-17 SG SG11202009692SA patent/SG11202009692SA/en unknown
- 2019-04-17 JP JP2020557212A patent/JP2021521785A/ja active Pending
- 2019-04-17 WO PCT/EP2019/060008 patent/WO2019202041A1/fr unknown
- 2019-04-17 TW TW108113353A patent/TW201945394A/zh unknown
- 2019-04-17 MA MA052285A patent/MA52285A/fr unknown
- 2019-04-17 AU AU2019256744A patent/AU2019256744A1/en not_active Abandoned
- 2019-04-17 MX MX2020010946A patent/MX2020010946A/es unknown
- 2019-04-17 EP EP19718695.0A patent/EP3781594A1/fr active Pending
- 2019-04-17 PE PE2020001543A patent/PE20210517A1/es unknown
- 2019-04-17 CN CN201980026851.4A patent/CN111989343B/zh active Active
- 2019-04-17 CA CA3095547A patent/CA3095547A1/fr not_active Abandoned
- 2019-04-17 KR KR1020207033026A patent/KR20210005639A/ko not_active Application Discontinuation
-
2020
- 2020-09-23 IL IL277559A patent/IL277559A/en unknown
- 2020-09-30 CO CONC2020/0012360A patent/CO2020012360A2/es unknown
- 2020-10-01 CL CL2020002539A patent/CL2020002539A1/es unknown
- 2020-10-15 PH PH12020500667A patent/PH12020500667A1/en unknown
- 2020-10-16 US US17/072,549 patent/US20210147554A1/en active Pending
-
2023
- 2023-02-27 JP JP2023028123A patent/JP2023081898A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PH12020500667A1 (en) | 2021-07-26 |
JP2021521785A (ja) | 2021-08-30 |
AU2019256744A1 (en) | 2020-11-19 |
SG11202009692SA (en) | 2020-11-27 |
CO2020012360A2 (es) | 2020-10-30 |
EP3781594A1 (fr) | 2021-02-24 |
KR20210005639A (ko) | 2021-01-14 |
MX2020010946A (es) | 2020-11-09 |
CA3095547A1 (fr) | 2019-10-24 |
JP2023081898A (ja) | 2023-06-13 |
CL2020002539A1 (es) | 2021-01-22 |
WO2019202041A1 (fr) | 2019-10-24 |
PE20210517A1 (es) | 2021-03-17 |
US20210147554A1 (en) | 2021-05-20 |
CN111989343A (zh) | 2020-11-24 |
TW201945394A (zh) | 2019-12-01 |
CN111989343B (zh) | 2023-12-26 |
AR115052A1 (es) | 2020-11-25 |
BR112020021111A2 (pt) | 2021-02-17 |
IL277559A (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52285A (fr) | Anticorps multispécifiques et leur utilisation | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
MA52284A (fr) | Anticorps anti-hla-g et leur utilisation | |
MA47311A (fr) | Anticorps anti-tgf-bêta et leur utilisation | |
MA53434A (fr) | Anticorps anti-tigit | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA44225A (fr) | Sulfonylurées et composés apparentés et leur utilisation | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA47694A (fr) | Anticorps anti-tigit | |
MA49034A (fr) | Anticorps anti-lag3 | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA50352A (fr) | Anticorps multispécifiques | |
MA43385A (fr) | Nouveaux anticorps anti-claudine et méthodes d'utilisation | |
MA45709A (fr) | Composés diazahétérobicycliques substitués et leur utilisation | |
MA44056A (fr) | Anticorps anti-rispéridone et leur utilisation |